Table 2.
Associations of clinical indicators and DDX60 expression levels with total survival in validation data.
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| HR (95% CI) | p values | HR (95% CI) | p values | ||
| Radiotherapy | |||||
| Yes | 210 (60.00%) | 0.596 (0.320–1.108) | 0.102 | 0.515 (0.221–1.200) | 0.126 |
| No | 140 (40.00%) | 1.000 | 1.000 | ||
| Age | |||||
| ≥60 | 170 (48.57%) | 2.296 (1.207–4.369) | 0.011 | 2.593 (1.132–5.940) | 0.025 |
| <60 | 180 (51.43%) | 1.000 | 1.000 | ||
| History of other malignancies | |||||
| Yes | 22 (6.29%) | 2.159 (0.760–6.131) | 0.149 | 2.724 (0.767–9.676) | 0.121 |
| No | 327 (93.43%) | 1.000 | 1.000 | ||
| NA | 1 (0.29%) | ||||
| Histologic type | |||||
| IDC | 229 (65.43%) | 0.861 (0.397–1.866) | 0.704 | 1.948 (0.732–5.184) | 0.182 |
| MBC | 33 (9.43%) | 1.509 (0.561–4.061) | 0.416 | 3.344 (0.948–11.794) | 0.061 |
| ILC | 82 (23.43%) | 1.000 | 1.000 | ||
| NA | 6 (1.71%) | ||||
| First surgical procedure | |||||
| Lumpectomy | 82 (23.43%) | 1.570 (0.607–4.059) | 0.352 | 1.392 (0.429–4.514) | 0.582 |
| Modified radical mastectomy | 112 (32.00%) | 1.159 (0.447–3.008) | 0.761 | 1.070 (0.329–3.484) | 0.911 |
| Others | 56 (16.00%) | 0.498 (0.154–1.607) | 0.243 | 0.413 (0.094–1.821) | 0.248 |
| A simple mastectomy | 76 (21.71%) | 1.000 | |||
| NA | 24 (6.86%) | ||||
| T stage | |||||
| T3/T4 | 57 (16.29%) | 1.429 (0.694–2.942) | 0.333 | 1.402 (0.555–3.543) | 0.475 |
| T1/T2 | 293 (83.71%) | 1.000 | 1.000 | ||
| N stage | |||||
| N2/N3 | 66 (18.86%) | 2.112 (0.982–4.539) | 0.056 | 3.440 (1.066–11.099) | 0.052 |
| N0/N1 | 277 (79.14%) | 1.000 | 1.000 | ||
| NA | 3 (2.00%) | ||||
| M stage | |||||
| M1 | 3 (0.86%) | 14.508 (3.343–62.960) | <0.001 | 2.975 (0.685–12.920) | 0.151 |
| M0 | 297 (84.86%) | 1.000 | 1.000 | ||
| NA | 50 (14.29%) | ||||
| ER status by IHC | |||||
| Positive | 266 (76.00%) | 0.726 (0.316–1.667) | 0.450 | 1.193 (0.375–3.793) | 0.765 |
| Negative | 61 (17.43%) | 1.000 | 1.000 | ||
| NA | 23 (6.57%) | ||||
| PR status by IHC | |||||
| Positive | 233 (66.57%) | 0.6274 (0.321–1.227) | 0.173 | 0.424 (0.146–1.232) | 0.120 |
| Negative | 91 (26.00%) | 1.000 | 1.000 | ||
| NA | 26 (7.43%) | ||||
| HER2 status by IHC | |||||
| Positive | 63 (18.00%) | 1.205 (0.468–3.107) | 0.699 | 1.354 (0.402–4.561) | 0.632 |
| Overexpression | 40 (11.43%) | 1.281 (0.370–4.440) | 0.696 | 0.934 (0.143–6.090) | 0.944 |
| Negative | 192 (54.96%) | 1.000 | 1.000 | ||
| NA | 55 (15.71%) | ||||
| Chemotherapy | |||||
| Yes | 302 (86.29%) | 0.678 (0.265–1.738) | 0.419 | 0.517 (0.139–1.579) | 0.247 |
| No | 47 (13.43%) | 1.000 | 1.000 | ||
| NA | 1 (0.29%) | ||||
| DDX60 expression | |||||
| High | 178 (50.86%) | 0.590 (0.310–1.123) | 0.108 | 0.527 (0.251–1.105) | 0.090 |
| Low | 172 (49.14%) | 1.000 | 1.000 | ||
Note. Abbreviations are the same as in Table 1.